指南与共识脊柱关节炎

银屑病关节炎临床实践指南的财务与非财务利益冲突及证据质量评估:日本与美国药品企业个人支付及作者自引率分析

Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors' Self-Citation Rate in Japan and the United States.
指南 / 共识 · Arthritis Care Res (Hoboken) · 2023-01-14

该回顾性分析评估了日本与美国银屑病关节炎临床实践指南作者的财务与非财务利益冲突,并评价指南证据质量与推荐强度。日本23名作者中21人(91.3%)获得支付,合计3,335,413美元;美国25名作者中21人(84.0%)获得支付,合计4,081,629美元。日本指南78.3%作者和美国指南48.0%作者存在未披露财务利益冲突。

要点

  • 日本银屑病关节炎指南23名作者中21人(91.3%)收到药品企业支付,合计3,335,413美元。
  • 美国银屑病关节炎指南25名作者中21人(84.0%)收到药品企业支付,合计4,081,629美元。
  • 日本指南71.4%、美国指南88.8%的银屑病关节炎推荐基于低或极低质量证据。

核心结论

  • 需要更严格的药品企业披露信息与医生自报信息交叉核对,以及更严格透明的利益冲突政策。

研究设计与样本

  • 回顾性分析,使用2016年至2018年日本主要药品企业支付数据和美国Open Payments数据库。
  • 纳入日本皮肤病学会(JDA)和美国风湿病学会(ACR)发布的银屑病关节炎临床实践指南全部作者,日本23名、美国25名。

主要发现

  • 日本23名作者中21人(91.3%)至少收到1笔支付,2016年至2018年合计3,335,413美元。
  • 美国25名作者中21人(84.0%)至少收到1笔支付,同期合计4,081,629美元。
  • 作者3年人均支付(均值±标准差)日本为145,018±114,302美元,美国为162,825±259,670美元。
  • 日本指南18名作者(78.3%)存在未披露财务利益冲突,价值474,663美元;美国指南12名作者(48.0%)存在未披露财务利益冲突,价值218,501美元。
  • 含至少1名指南作者引用的比例占总引用比例日本为3.4%,美国为33.6%。

关键数值与推荐

  • 日本指南71.4%的银屑病关节炎推荐基于低或极低质量证据。
  • 美国指南88.8%的银屑病关节炎推荐基于低或极低质量证据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess financial conflicts of interest (COI) and nonfinancial COI among psoriatic arthritis (PsA) clinical practice guideline (CPG) authors in Japan and the US, and to evaluate the quality of evidence and strength of recommendations of PsA CPGs. METHODS: We performed a retrospective analysis using payment data from major Japanese pharmaceutical companies and the US Open Payments Database from 2016 to 2018. All authors of PsA CPGs issued by the Japanese Dermatological Association (JDA) and American College of Rheumatology (ACR) were included. RESULTS: Of 23 CPG authors in Japan, 21 (91.3%) received at least 1 payment, with a combined total of $3,335,413 between 2016 and 2018. Regarding 25 US authors, 21 (84.0%) received at least 1 payment, with a combined total of $4,081,629 during the same period. The 3-year combined mean ± SD payment per author was $145,018 ± $114,302 in Japan and $162,825 ± $259,670 in the US. A total of 18 authors (78.3%) of the JDA PsA CPG and 12 authors (48.0%) of the ACR PsA CPG had undisclosed financial COI worth $474,663 and $218,501, respectively. The percentage of citations with at least 1 CPG author relative to total citations was 3.4% in Japan and 33.6% in the US. In sum, 71.4% and 88.8% of recommendations for PsA in the JDA and ACR were supported by low or very low quality of evidence. CONCLUSION: More rigorous cross-checking of information disclosed by pharmaceutical companies and self-reported by physicians and more stringent and transparent COI policies are necessary.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Mamada H, Murayama A, Kamamoto S, et al. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors' Self-Citation Rate in Japan and the United States. Arthritis Care Res (Hoboken). 2023. PMID: 36194077. doi:10.1002/acr.25032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。